SLS
Sellas Life Sciences Group I
NASDAQ · Biotechnology
$3.73
+0.20 (+5.67%)
Open$3.59
Previous Close$3.53
Day High$3.83
Day Low$3.55
52W High$5.18
52W Low$0.95
Volume—
Avg Volume5.75M
Market Cap531.31M
P/E Ratio—
EPS$-0.29
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+808.8% upside
Current
$3.73
$3.73
Target
$33.90
$33.90
$25.20
$33.90 avg
$43.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Net Income | 19.39M | 21.88M | 20.34M |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |
| Rev Growth | -7.4% | -1.2% | +17.7% |
| Debt/Equity | 0.38 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |